The Randomized Etoricoxib Study in Patients With Osteoarthritis Not Responding to Analgesic Drugs - THE RESPOND-EUROPE STUDY.

Trial Profile

The Randomized Etoricoxib Study in Patients With Osteoarthritis Not Responding to Analgesic Drugs - THE RESPOND-EUROPE STUDY.

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 16 Apr 2015

At a glance

  • Drugs Etoricoxib (Primary)
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Therapeutic Use
  • Acronyms RESPOND-EUROPE
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 15 Dec 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 09 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top